Specialised Centre for Emergency and Disaster Pharmacy, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Pharmacy, Geneva University Hospitals, Geneva, Switzerland.
BMC Health Serv Res. 2023 Oct 20;23(1):1134. doi: 10.1186/s12913-023-10105-6.
The COVID-19 pandemic strained healthcare systems immensely as of 2020. Switzerland's hospital pharmacies' responses during the first wave were surveyed with a view to improving the quality of pharmaceutical management in future health crises.
An online survey was sent to the heads of all of Switzerland's hospital pharmacies. The questionnaire was organised into eleven sections of questions covering many topics regarding the management of COVID-19's first wave. Data collection occurred from May to June 2020.
Analyses were performed using the 43 questionnaires (66%), with at least one answer per questionnaire, out of 65 distributed. Seventeen of 41 pharmacies responding (41%) had existing standard operating procedures or pandemic plans and 95% of these (39/41) set up crisis management steering committees. Twenty-nine of 43 pharmacies responding (67%) created new activities to respond to the pandemic's specific needs. Twenty-six of 39 pharmacies responding (67%) created new drug lists for: COVID-19-specific treatments (85%; 22/26), sedatives (81%; 21/26), anaesthetics (77%; 20/26) and antibiotics (73%; 19/26). Drug availability in designated COVID-19 wards was managed by increasing existing stocks (54%; 22/41 pharmacies) and creating extra storage space (51%; 21/41). Two drugs generated the greatest concern about shortages: propofol (49%; 19/39 pharmacies) and midazolam (44%; 17/39). Remdesivir stocks ran out in 26% of pharmacies (10/39). Twelve of 43 pharmacies (28%) drafted specific new documents to respond to medical needs regarding drug administration, 12 (28%) did so for drug preparation and 10 (23%) did so for treatment choices.
Switzerland's hospital pharmacies encountered many challenges related to the COVID-19 crisis and had to find solutions quickly, effectively and safely. The survey highlighted the key role that hospital pharmacies played in many aspects of the pandemic by providing logistical and clinical support to medical and nursing care teams. The lessons and experiences outlined could be used to improve the quality of hospital pharmacies' readiness for similar future events.
2020 年,COVID-19 大流行极大地考验了医疗系统。本研究旨在调查瑞士医院药房在第一波疫情期间的应对措施,以提高未来卫生危机期间药学管理的质量。
对瑞士所有医院药房的负责人进行了在线调查。问卷分为十一个部分,涵盖了与 COVID-19 第一波管理相关的许多主题。数据收集于 2020 年 5 月至 6 月进行。
对 65 份问卷中的 43 份(66%)进行了分析,每份问卷至少有一个答案。41 家回应的药房中有 17 家(41%)有现有的标准操作程序或大流行计划,其中 95%(39/41)设立了危机管理指导委员会。43 家回应的药房中有 29 家(67%)开展了新活动以应对大流行的特殊需求。39 家回应的药房中有 26 家(67%)为 COVID-19 特定治疗药物(85%;22/26)、镇静剂(81%;21/26)、麻醉剂(77%;20/26)和抗生素(73%;19/26)制定了新药单。通过增加现有库存(54%;22/41 家药房)和创造额外存储空间(51%;21/41 家药房)来管理指定 COVID-19 病房的药物供应。有两种药物短缺引起了极大关注:丙泊酚(49%;19/39 家药房)和咪达唑仑(44%;17/39 家药房)。雷米昔韦在 26%的药房(10/39 家)库存耗尽。43 家药房中有 12 家(28%)起草了专门的新文件,以满足药物管理方面的医疗需求,12 家(28%)为药物准备起草了新文件,10 家(23%)为治疗选择起草了新文件。
瑞士医院药房在 COVID-19 危机中遇到了许多挑战,必须迅速、有效和安全地找到解决方案。该调查强调了医院药房在大流行期间通过向医疗和护理团队提供后勤和临床支持,在许多方面发挥的关键作用。概述的经验教训可用于提高医院药房为类似未来事件做好准备的质量。